CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

To determine the safety and efficacy of CD5789 (trifarotene) 50 µg/g cream in the long-term
treatment (up to 52 Weeks) of subjects with acne vulgaris. Efficacy will be evaluated as a
secondary objective.

Inclusion Criteria:

- The Subject has a facial acne severity grade of IGA grade 3 (moderate) at Screening
and Baseline visits.

- The Subject has a minimum of 20 inflammatory lesions and 25 non-inflammatory lesions
at Screening and Baseline visits on the face.

- Exclusion Criteria:

- The subject has severe forms of acne (acne conglobata, acne fulminans) or secondary
acne form (chloracne, drug-induced acne, etc.).

- The Subject has more than 1 nodule on the face at Screening and at Baseline visits.

- The Subject has any acne cyst on the face at Screening and at Baseline visits.